Samsung Biologics America (SBA) has entered into an agreement with GSK to acquire 100% of Human Genome Sciences, located in Rockville, Maryland, for $280 million.

The move marks a significant expansion of the company’s global footprint and long-term commitment to the U.S. market. SBA is a wholly owned U.S. subsidiary of Samsung Biologics, a South Korea-based contract development and manufacturing organization. The move establishes Samsung Biologics’ first U.S.-based manufacturing site.

The Rockville facility comprises two cGMP plants, and Samsung Biologics will retain approximately 500 employees, with plans to further invest in expanding capacity and upgrading technology. “This landmark acquisition is a testament to our unwavering commitment to advancing global healthcare and bolstering our manufacturing capabilities in the U.S. The investment will enable us to deepen our collaboration with federal, state, and local stakeholders to best serve our customers and partners while ensuring a reliable and stable supply of life-saving therapeutics,” said John Rim, CEO and President of Samsung Biologics.